Kura Oncology, Inc. (NasdaqGS:KURA) may also use a portion of the net proceeds of up to $25 million to acquire or invest in businesses, products and technologies that are complementary to our own, although we have no current plans, commitments or agreements with respect to any acquisitions as of the date of this prospectus supplement.